Strongbridge Drug Patent Portfolio
Strongbridge owns 1 orange book drug protected by 8 US patents Given below is the list of Strongbridge's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11020393 | Methods of treating disease with levoketoconazole | 02 Mar, 2040 | Active |
| US11278547 | Methods of treating disease with levoketoconazole | 02 Mar, 2040 | Active |
| US11903940 | Methods of treating disease with levoketoconazole | 02 Mar, 2040 | Active |
| US10098877 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 10 Jan, 2026 | Active |
| US10517868 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 10 Jan, 2026 | Active |
| US10835530 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 10 Jan, 2026 | Active |
| US11478471 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 10 Jan, 2026 | Active |
| US9918984 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions | 10 Jan, 2026 | Active |
Latest Legal Activities on Strongbridge's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Strongbridge.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 06 May, 2024 | US10835530 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9918984 |
|
Recordation of Patent Grant Mailed
Critical
| 20 Feb, 2024 | US11903940 |
| Patent eGrant Notification | 20 Feb, 2024 | US11903940 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 20 Feb, 2024 | US11903940 |
| Recordation of Patent eGrant | 20 Feb, 2024 | US11903940 |
|
Email Notification
Critical
| 20 Feb, 2024 | US11903940 |
| Mail Patent eGrant Notification | 20 Feb, 2024 | US11903940 |
|
Email Notification
Critical
| 01 Feb, 2024 | US11903940 |
|
Issue Notification Mailed
Critical
| 31 Jan, 2024 | US11903940 |
|
Application Is Considered Ready for Issue
Critical
| 10 Jan, 2024 | US11903940 |
| Dispatch to FDC | 10 Jan, 2024 | US11903940 |
|
Issue Fee Payment Verified
Critical
| 05 Jan, 2024 | US11903940 |
|
Issue Fee Payment Received
Critical
| 05 Jan, 2024 | US11903940 |
|
Electronic Review
Critical
| 12 Dec, 2023 | US11903940 |
Strongbridge's Family Patents
Strongbridge drugs have patent protection in a total of 21 countries. It's US patent count contributes only to 31.7% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Strongbridge Drug List
Given below is the complete list of Strongbridge's drugs and the patents protecting them.
1. Recorlev
Recorlev is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11020393 | Methods of treating disease with levoketoconazole |
02 Mar, 2040
(14 years from now)
| Active |
| US11278547 | Methods of treating disease with levoketoconazole |
02 Mar, 2040
(14 years from now)
| Active |
| US11903940 | Methods of treating disease with levoketoconazole |
02 Mar, 2040
(14 years from now)
| Active |
| US10098877 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
10 Jan, 2026
(7 months from now)
| Active |
| US10517868 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
10 Jan, 2026
(7 months from now)
| Active |
| US10835530 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
10 Jan, 2026
(7 months from now)
| Active |
| US11478471 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
10 Jan, 2026
(7 months from now)
| Active |
| US9918984 | Methods and compositions for treating diabetes, metabolic syndrome and other conditions |
10 Jan, 2026
(7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Recorlev's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List